Results 131 to 140 of about 114,714 (200)

Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma. [PDF]

BMC Med Genomics, 2022
Mo C, Wu Y, Ma J, Xie L, Huang Y, Xu Y, Peng H, Chen Z, Zeng M, Mao R.   +9 more
europepmc   +1 more source

Cyclin-Dependent Kinases [PDF]

, 2011
openaire   +1 more source

Cyclin-Dependent Kinase [PDF]

, 2020
openaire   +1 more source

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis. [PDF]

J Pharm Policy Pract
Elazzazy S, Hisham Al-Ziftawi N, Shafei L, Mohamed Ibrahim MI, Bojassoum S, Hamad A.   +5 more
europepmc   +1 more source

Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation. [PDF]

Sci Rep, 2023
Ford K, Munson BP, Fong SH, Panwala R, Chu WK, Rainaldi J, Plongthongkum N, Arunachalam V, Kostrowicki J, Meluzzi D, Kreisberg JF, Jensen-Pergakes K, VanArsdale T, Paul T, Tamayo P, Zhang K, Bienkowska J, Mali P, Ideker T.   +18 more
europepmc   +1 more source

Targeting CDK4 and CDK6 in cancer. [PDF]

Nat Rev Cancer, 2022
Goel S, Bergholz JS, Zhao JJ.
europepmc   +1 more source

Knockout of cyclin-dependent kinases 8 and 19 leads to depletion of cyclin C and suppresses spermatogenesis and male fertility in mice. [PDF]

Elife
Bruter AV, Varlamova EA, Stavskaya NI, Antysheva ZG, Manskikh VN, Tvorogova AV, Korshunova DS, Khamidullina AI, Utkina MV, Bogdanov VP, Baikova IP, Nikiforova AI, Albert EA, Maksimov DO, Li J, Chen M, Schools GP, Feoktistov AV, Shtil AA, Roninson IB, Mogila VA, Silaeva YY, Tatarskiy VV.   +22 more
europepmc   +1 more source

Antagonistic effect of cyclin-dependent kinases and a calcium-dependent phosphatase on polyglutamine-expanded androgen receptor toxic gain of function. [PDF]

Sci Adv, 2023
Piol D, Tosatto L, Zuccaro E, Anderson EN, Falconieri A, Polanco MJ, Marchioretti C, Lia F, White J, Bregolin E, Minervini G, Parodi S, Salvatella X, Arrigoni G, Ballabio A, La Spada AR, Tosatto SCE, Sambataro F, Medina DL, Pandey UB, Basso M, Pennuto M.   +21 more
europepmc   +1 more source

Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy. [PDF]

Oncologist
Jacobs F, Gaudio M, Andreottola C, Borroni R, Benvenuti C, Saltalamacchia G, Gerosa R, Canzian J, Tiberio P, Torrisi R, Masci G, Miggiano C, Zambelli A, Santoro A, De Sanctis R.   +14 more
europepmc   +1 more source

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action. [PDF]

Int J Mol Sci, 2021
Łukasik P, Baranowska-Bosiacka I, Kulczycka K, Gutowska I.   +3 more
europepmc   +1 more source